Stock comparison
Biogen
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BIIB
Biogen
Market cap
$28.61B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BIIB | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 53C | 77B | LMAT |
| Benjamin Graham | 63C | 89A | LMAT |
| Philip Fisher | 43D | 81C | LMAT |
| Peter Lynch | 21F | 67B | LMAT |
| Joel Greenblatt | 34F | 56D | LMAT |
| Charlie Munger | 48D | 68D | LMAT |
| Terry Smith | 49D | 69D | LMAT |
Side-by-side metrics
| Metric | BIIB | LMAT |
|---|---|---|
| Market cap | $28.61B | $2.23B |
| P/E (TTM) | 21.2x | 37.1x |
| EV/EBIT | 17.3x | 36.6x |
| ROIC (TTM) | 5.44% | 9.43% |
| Gross margin | 69.77% | 72.39% |
| Net margin | 13.92% | 24.35% |
| Revenue CAGR 5y | -2.78% | 12.75% |
| EPS CAGR 5y | -4.05% | 19.04% |
| Debt / Equity | 0.4x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BIIB leads on
- Market cap$28.61Bvs $2.23B+92%
- EV/EBIT17.3xvs 36.6x+53%
- P/E (TTM)21.2xvs 37.1x+43%
- Debt / Equity0.4xvs 0.5x+25%
LMAT leads on
- Revenue CAGR 5y12.75%vs -2.78%+122%
- EPS CAGR 5y19.04%vs -4.05%+121%
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 13.92%+43%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.